Prof Philippe Moreau speaks to ecancer about the use of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd quad regimen) in newly developed multiple myeloma, and the MIDAS and CONCEPT studies.

Induction therapy is being used more and more now as first-line therapy for NDMM.

Prof Moreau provides an overview of the different quadruplet therapies that can be used as first-line therapy.

He then delves into the background and results of the minimal residual disease-adapted strategy (MIDAS) study.

Prof Moreau highlights the impressive results of the study in terms of MRD negativity rates and underscores their significance.

The quadruplet combination used in the study proved to be highly feasible for patients with a good safety profile.

He also discusses the placement of this study in the treatment landscape and touches upon the CONCEPT study, providing insight into where the CONCEPT data fits within the overall treatment landscape.